In cases of moderate or severe disease, IBD physicians can rely on anti-tumor necrosis factor alfa (anti-TNFα), anti-integrins, anti-interleukin 23 (anti-IL23), and Janus kinase inhibitors (anti-JAK) [10,11]. The gene discussed is IL37; the disease is inflammatory bowel disease.